RX 77368

Drug Profile

RX 77368

Alternative Names: Thymoliberin

Latest Information Update: 18 Sep 1997

Price : $50

At a glance

  • Originator Reckitt Benckiser
  • Developer Ferring Pharmaceuticals; Reckitt Benckiser
  • Class Antidepressants; Cytoprotectives
  • Mechanism of Action Thyrotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Learning disorders; Major depressive disorder; Motor neuron disease; Peptic ulcer

Most Recent Events

  • 18 Sep 1997 Discontinued-II for Motor neuron disorders in Sweden (unspecified route)
  • 18 Sep 1997 Discontinued-Preclinical for Learning disorders in United Kingdom (unspecified route)
  • 18 Sep 1997 Discontinued-Unspecified Phase in Depression in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top